Therapeutic potential of enhancer of zeste homolog 2 in autoimmune diseases. (2nd December 2019)

• Record Type: Journal Article
• Authors: Yang, Yue-Xin; Shen, Hui-Hui; Cao, Fan; Xie, Liang-Yu; Zhu, Guang-Lin; Sam, Napoleon Bellua; Wang, De-Guang; Pan, Hai-Feng
• Is Part Of: Expert opinion on therapeutic targets. Volume 23:Number 12(2019:Dec.)
• Page Start: 1015
• Page End: 1030
• Publication Date: 2019-12-02
• Subjects: EZH2 -- autoimmune disease -- epigenetic modifications -- immunological dysfunction -- therapeutic potential; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2019.1696309
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Autoimmune diseases (ADs) are idiopathic and heterogeneous disorders with contentious pathophysiology. Great strides have been made in epigenetics and its involvement in ADs. Zeste homolog 2 (EZH2) has sparked extensive interest because of its pleiotropic roles in distinct pathologic contexts. Areas covered : This review summarizes the epigenetic functions and the biological significance of EZH2 in the etiology of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), inflammatory bowel disease (IBD), multiple sclerosis (MS), and systemic sclerosis (SSc). A brief recapitulation of the therapeutic potential of EZH2 targeting is provided. Expert opinion : There are questions marks and controversies surrounding the feasibility and safety of EZH2 targeting; it is recommended in RA and SLE, but queried in T1D, IBD, MS, and SSc. Future work should focus on contrast studies, systematic analyses and preclinical studies with optimizing methodologies. Selective research studies conducted in a stage-dependent manner are necessary because of the relapsing-remitting clinical paradigms.